scott.kogan@ucsf.edu
(415) 514-1590 (voice)
(415) 353-1106 (fax)

Box 0100, UCSF; San Francisco, CA 94143-0100

Harvard College, Cambridge, MA, A.B., 1986, Biochemical Sciences
University of California San Francisco, M.D., 1991, Medicine
Laboratory Medicine Residency, UCSF, 1991-1993, Laboratory Medicine
Hematopathology Fellowship, UCSF, 1997-1998, Hematopathology

Out of 49

Kogan SC; Doherty M; Gitschier J. An Improved Method for Prenatal Diagnosis of Genetic Diseases by Analysis of Amplified DNA Sequences: Application to Hemophilia A. N Engl J Med 1987, 317:985-990.

Brown, DE*; Kogan, SC*; Lagasse, E; Weissman, IL; Alcalay, M; Pelicci, P; Atwater, S; Bishop, JM. A PML-RARATransgene Initiates Murine Acute Promyelocytic Leukemia. Proc Natl Acad Sci USA 1997, 94:2551-2556. *These authors contributed equally to this work.

Kogan, SC; Hong, SH; Shultz, DB; Privalsky, ML; Bishop, JM. Leukemia Initiated by PMLRAR: the PML Domain Plays a Critical Role while Retinoic Acid Mediated Transactivation is Dispensable. Blood (Plenary Paper) 2000, 95:1541-1550.

Kogan, SC; Brown, DE; Shultz, DB; Tran, BH; Lallemand-Breitenbach, V; Guillemin, MC; Lagasse, E; Weissman, IL; Bishop, JM. BCL-2 Cooperates with PMLRAR to Block Neutrophil Differentiation and Initiate Acute Leukemia. J Exp Med 2001, 193:531-544.

Truong, BH; Lee, YJ; Lodie, TA; Park, DJ; Perrotti, D; Watanabe, N; Koeffler, HP; Nakajima, H; Tenen, DG; Kogan, SC. CCAAT/Enhancer Binding Proteins Repress the Leukemic Phenotype of Acute Myeloid Leukemia. Blood, 2003, 101:1141-1148.

Sohal, J; Phan, VT; Chan, PV; Davis, EM; Patel, B; Kelly, LM; Abrams, T; O'Farrell, AM; Gilliland, DG; LeBeau, MM; Kogan, SC. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood, 2003, 101: 3188-3197.

Phan, VT; Shultz, DB; Truong, BH; Blake, TJ; Brown, AL; Gonda, TJ; Le Beau, MM; Kogan, SC. Cooperation of Cytokine Signaling with Chimeric Transcription Factors in Leukemogenesis: PML-RAR blocks growth factor mediated differentiation. Mol Cell Biol, 2003, 23: 4573-4585.

Le Beau, MM; Davis, EM; Patel, B; Phan, VT; Sohal, J; Kogan, SC. Recurring Chromosomal Abnormalities in Leukemia in PML-RARA Transgenic Mice Identify Cooperating Events and Genetic Pathways to Acute Promyelocytic Leukemia. Blood, 2003, 102:1072-1074.

Wang, J; Iwasaki, H; Krivtsov, A; Febbo, PG; Thorner, AR; Ernst, P; Anastasiadou, E; Kutok, JL; Kogan, SC; Zinkel, SS; Fisher, JK; Hess, JL; Golub, TR; Armstrong, SA; Akashi, K; Korsmeyer, SJ. Conditional MLL-CBP Targets GMP and Models Therapy-Related Myeloproliferative Disease. EMBO J. 2005, 24:368-381.

Zhu, J; Zhou, J; Peres, L; Riacoux, F; Honoré, N; Kogan, S; de Thé, H. A Sumolation site in PML/RARA is Essential for Leukemic Transformation. Cancer Cell 2005, 7:143-153.

Chao, RC; Pyzel, U; Fridlyand, J; Kuo, YM; Teel, L; Haaga, J; Borowsky, A; Horvai, A; Kogan, SC; Bonifas, J; Huey, B; Jacks, TE; Albertson, DG; Shannon, KM. Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell, 2005, 8:337-348.

Yamashita, N; Osato, M; Huang, L; Yanagida, M; Kogan, SC; Iwasaki, M; Nakamura, T; Shigesada, K; Asou, N; Ito, Y. Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. Br J Haematol, 2005, 131:495-507.

Rego, EM; Ruggero, D; Tribioli, C; Cattoretti, G; Kogan, S; Redner, RL; Pandolfi, PP. Leukemia with distinct phenotypes in transgenic mice expressing PML/RARalpha, PLZF/RARalpha or NPM/RARalpha. Oncogene, 2006, 25:1974-1979.

Liu, W; Guo, M; Xu, YB; Dao, L; Zhou, ZN; Wu, YL; Chen, Z; Kogan, SC; Chen, GQ. Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood, 2006, 107:698-707.

Kuo, YH; Landrette, SF; Heilman, SA; Perrat, PN; Garrett, L; Liu, PP; Le Beau, MM; Kogan, SC; Castilla, LH. Cbfβ-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell, 2006, 9:57-68.

Sternsdorf, T; Phan, V; Maunakea, ML; Ocampo, C; Sohal, J; Silletto, A; Galimi, F; LeBeau, MM; Evans, RM; Kogan, SC. Forced Retinoic Acid Receptor alpha Homodimers Prime Mice for APL-like Leukemia. Cancer Cell, 2006, 9:81-94.

Yin, B; Kogan, SC; Largaespada, DA. Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia. Exp Hematol, 2006, 34:631-641.

Zhuang, D; Qiu, Y; Kogan, SC; Dong, F. Increased C/EBPepsilon expression and premature apoptosis in myeloid cells expressing Gfi-1 N382S mutant associated with severe congenital neutropenia. J Biol Chem, 2006, 281:10745-10751.

Wendel, HG; de Stanchina, E; Cepero, E; Ray, S; Fridman, JS; Emig, M; Veach, DR; Bornmann, WG; Clarkson, B; McCombie, WR; Kogan, SC; Hochhaus, A; Lowe, SW. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci USA, 2006, 103:7444-7449.

Lee, YJ; Jones, LC; Timchenko, NA; Perrotti, D; Tenen, DG; Kogan SC. CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but they differ in their anti-leukemic activities. Blood, 2006, 108:2416-2419.

Forsberg, C; Serwold, T; Kogan, S; Weissman, IL; Passegué, E. Megakaryocyte-Erythroid potential of hematopoietic stem and progenitor cells: Fully multipotent Flk2/Flt3-positive early progenitors. Cell, 2006, 126:415-426.

Wendel, HG; Malina, A; Zhao, Z; Zender, L; Kogan, SC; Cordon-Cardo, C; Pelletier, J; Lowe, SW. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res, 2006, 66:7639-7646.

12/7/06